When was RegeneRx founded?

RegeneRx was founded in 1982 and raised its 1st funding round 20 years after it was founded.

Where is RegeneRx located?

RegeneRx is headquartered in Rockville, United States.

How many employees does RegeneRx have?

As of Jul 31, 2026, the latest employee count at RegeneRx is 7.

Is RegeneRx a funded company?

RegeneRx is a funded company, having raised a total of $1.72M across 20 funding rounds to date. The company's 1st funding round was a $***** Unattributed round, raised on Apr 2002.

When was the latest funding round of RegeneRx?

RegeneRx's latest funding was a $***** Post IPO round on Jun 28, 2021, with participation from 0 investor. Its primary sector is Wound Care. In United States, the Wound Care sector has seen $52.7M in funding in 2026 to date.

What is the annual revenue of RegeneRx?

Annual revenue of RegeneRx is less than $1M as on Dec 31, 2022

Where does RegeneRx rank among its competitors?

RegeneRx ranks 20th amongst 211 active competitors, of which 44 are funded. It stands 6th in terms of total funding among its competitors. The most recent competitor to raise funding was BioStem Technologies, which secured $2.5M in May, 2026.

Who are the top competitors of RegeneRx?

RegeneRx's top competitors include SolasCure, SanuWave and Nuo Therapeutics. Among them, BioStem Technologies secured the most recent funding round in May, 2026.

RegeneRx - 2026 Company Profile, Team, Funding, Competitors & Financials

Company Details

Biopharmaceutical firm focused on tissue protection, repair, and regeneration. The company develops novel pharmaceuticals for tissue and organ damage caused by disease or trauma. Its primary focus is on Thymosin beta 4 (Tβ4) to treat ophthalmic indications like neurotrophic keratitis (NK) and dry eye disease (DED). Their ophthalmic drug candidate, RGN-259, is in phase clinical trials for NK treatment. They operate through partnerships in major territories, including the U.S., Canada, China, Pan Asia, and the EU. The company is involved in clinical development, aiming to confirm previous efficacy results and shorten the development period. Their eye drop is developed to reduce damage and improve healing for ophthalmic indications. Thymosin beta 4, the active ingredient, promotes cell migration, cytoprotection, wound healing, and has anti-inflammatory properties. This is a B2B business model.

Key Metrics

Founded Year

1982

Location

Rockville, United States

Stage

Public

Total Funding

$1.72M in 20 rounds

Latest Funding Round

Post IPO, Jun 28, 2021, $*****

Investors

HHS & 1 more

Ranked

20^th among 211 active competitors

Annual Revenue

$0 - $1M as on Dec 31, 2022

Employee Count

7 as on Jul 31, 2026

Similar Companies

SolasCure & 244 more

Exit Details

Public

View RegeneRx's full profile

RegeneRx is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Reports
REGENERX BIOPHARMACEUTICALS INC CIN: 707511 , United States, Active	May 12, 1982	$0 - $1M (As on Dec 31, 2022)	3 (As on Dec 31, 2021)	-

RegeneRx got listed on Dec 23, 2010.

Click here to take a look at RegeneRx's IPO in detail

RegeneRx has raised a total funding of $1.72M over 20 rounds. Its first funding round was on Apr 2002. RegeneRx has 2 institutional investors.

Here is the list of recent funding rounds of RegeneRx:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jun 28, 2021	3738805	Post IPO	9106617	8851649	4315113	8508877
Oct 21, 2020	7578639	Post IPO	9175697	5252510	4564077	ReGenTree
May 28, 2019	5416612	Post IPO	2390942	7017216	1698698	6000034

Access funding benchmarks and valuations. Sign up today!

View details of RegeneRx's funding rounds and investors

RegeneRx's employee count trend

RegeneRx has 7 employees as of Jul 26. Here is RegeneRx's employee count trend over the years:

Uncover RegeneRx's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of RegeneRx include SolasCure, SanuWave and Nuo Therapeutics. Here is the list of Top 10 competitors of RegeneRx, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	SolasCure 2017, Cambridge (United Kingdom), Series B	Developer of biologic therapies for the treatment of chronic wounds	$34.1M	Seneca, Tricor Group & 66 others	62/100
2nd	SanuWave 2005, Alpharetta (United States), Public	Developer of Noninvasive devices, and biologics for wound healing	$1.43M	CIT, Kingswood Capital Markets	60/100
3rd	Nuo Therapeutics 2001, Gaithersburg (United States), Public	Developer of regenerative products for wound care	$69.1M	MidCap Financial, Maryland Department of Commerce ... & 2 others	58/100
4th	Sanara MedTech 1982, Fort Worth (United States), Public	Developer of therapeutics for infectious disease	-	BlueIO, The Catalyst Group	56/100
5th	TargED 2020, Utrecht (Netherlands), Series A	Developer of biological drugs for the treatment of thrombosis	$82.8M	Sunstone, Hadean Ventures & 8 others	56/100
6th	MediWound 2001, Yavne (Israel), Public	Developer of enzymatic therapeutic solutions for tissue repair and regeneration	$18M	Point72, New Era Capital Partners & 10 others	54/100
7th	Tissue Regenix 2006, Swillington (United Kingdom), Public	Developer of regenerative medical devices by using cell technology	-	Harwood Capital, IP Group & 2 others	53/100
8th	BioStem Technologies 2006, Pompano Beach (United States), Public	Provider of placental-based amniotic tissue products	-	-	51/100
9th	Next Science 2012, Jacksonville (United States), Public	Redefining healing through science, innovation, and commitment to better patient outcomes	-	-	51/100
10th	Mosaic Biosciences 2009, Boulder (United States), Series B	Protein and antibody therapeutics discovery from concept to clinical candidate	$14.7M	Healthcare Ventures, Telegraph Hill Partners ... & 5 others	48/100
20th	RegeneRx 1982, Rockville (United States), Public	Biopharmaceutical firm focused on tissue protection, repair, and regeneration	$1.72M	HHS, ReGenTree	45/100